The Conte Center for Schizophrenia Research
康特精神分裂症研究中心
基本信息
- 批准号:8502370
- 负责人:
- 金额:$ 191.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-23 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimal ModelAuditoryAuditory systemAutopsyBiometryBrainCollaborationsD AspartateDevelopmentDiseaseDopamineEffectivenessFaceFunctional disorderGenerationsGenesGlutamatesGoalsHospitalsHumanImageImpairmentInstitutesInterventionInvestigationLasersMediatingMental disordersMethodsMicroscopyModelingNeurocognitive DeficitNew YorkPatient RecruitmentsPatientsPharmaceutical PreparationsPhysiologicalPopulationPrimatesProcessResearchResearch PersonnelSarcosineSchizophreniaSensorySensory ProcessSymptomsUniversitiesVisionVisual system structureaspartate receptorbasedata managementmedical schoolsneurochemistryneurogeneticsneurophysiologyneurotransmissionnovelobject recognition
项目摘要
This is an application for a new Conte Center for Schizophrenia Research based at the New York University School of Medicine (NYUSoM) and the affiliated Nathan Kline Institute for Psychiatric Research (NKI). Schizophrenia (SZ) is associated with sensory processing deficits that represent a core, but understudied, connponent of the disorder. In the auditory system, patients show deficits in basic processes such as tone matching and auditory mismatch negativity (MMN) generation. In the visual system, patients show deficits in processes such as contrast gain and integration that contribute to higher order impairments in processes such as object recognition and face recognition. Sensory deficits may relate specifically to impairments in Nmethyl-
D-aspartate (NMDA) receptor-mediated neurotransmission, and are especially amenable to translational investigation using human and animal models. The Center consists of 6 projects and 3 cores, which build from pre-existing collaborations among Center investigators. Projects 1, 2 and 4 are based at NKI/NYSoM and utilize human (Javitt) and primate (Schroeder) neurophysiological, and human postmortem/laser capture microscopy/gene array (Ginsberg/Smiley) approaches to the study of sensory cortical dysfunction and impaired functional connectivity in SZ. Project 3 (Hlllyard) is based at UCSD and investigates modulatory processes underlying normal visual function. Project 5 (Cornblatt) is based at Zucker Hillside Hospital and investigates sensory processing dysfunction within the SZ prodrome. Finally, Project 6 (Weiser) is based at Sheba Hospital/Tel Aviv University and evaluates effectiveness of sarcosine (N-methylglycine), a naturally occurring NMDA agonist not currently available in the US. Cores are devoted to administration (Javitt), patient recruitment/assessment (Butler) and data management/biostatistics (Robinson/Petkova). Although traditional models of SZ focus on dopamine, more recent models focus on underlying glutamatergic dysfunction, and have received support from neurogenetic, imaging, and treatment studies, as well as challenge studies with putative NMDA antagonists. The overall goal of the Center is to develop new assessment and intervention approaches for schizophrenia based upon glutamatergic models.
这是一个新的精神分裂症研究中心的申请,该中心位于纽约大学医学院(NYUSoM)和附属的内森克莱恩精神病学研究所(NKI)。精神分裂症(SZ)与感觉处理缺陷有关,这是该疾病的一个核心组成部分,但尚未得到充分研究。在听觉系统中,患者表现出音调匹配和听觉失配负性(MMN)产生等基本过程的缺陷。在视觉系统中,患者表现出对比度增益和整合等过程的缺陷,这些缺陷导致了物体识别和面部识别等过程的高阶损伤。感觉缺陷可能与Nmethyl-的损伤有关
项目成果
期刊论文数量(24)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Gamma band activity and the P3 reflect post-perceptual processes, not visual awareness.
- DOI:10.1016/j.neuroimage.2014.07.024
- 发表时间:2014-11-01
- 期刊:
- 影响因子:5.7
- 作者:Pitts MA;Padwal J;Fennelly D;Martínez A;Hillyard SA
- 通讯作者:Hillyard SA
Audio-visual synchrony modulates the ventriloquist illusion and its neural/spatial representation in the auditory cortex
- DOI:10.1016/j.neuroimage.2014.04.077
- 发表时间:2014-09-01
- 期刊:
- 影响因子:5.7
- 作者:Bonath, Bjoern;Noesselt, Toemme;Hillyard, Steven A.
- 通讯作者:Hillyard, Steven A.
Spatio-temporal patterns of brain activity distinguish strategies of multiple-object tracking.
大脑活动的时空模式区分了多目标跟踪的策略。
- DOI:10.1162/jocn_a_00455
- 发表时间:2014
- 期刊:
- 影响因子:3.2
- 作者:Merkel,Christian;Stoppel,ChristianM;Hillyard,StevenA;Heinze,Hans-Jochen;Hopf,Jens-Max;Schoenfeld,MirceaAriel
- 通讯作者:Schoenfeld,MirceaAriel
Intrinsic brain subsystem associated with dietary restraint, disinhibition and hunger: an fMRI study.
与饮食限制、去抑制和饥饿相关的内在大脑子系统:一项功能磁共振成像研究。
- DOI:10.1007/s11682-015-9491-4
- 发表时间:2017
- 期刊:
- 影响因子:3.2
- 作者:Zhao,Jizheng;Li,Mintong;Zhang,Yi;Song,Huaibo;vonDeneen,KarenM;Shi,Yinggang;Liu,Yijun;He,Dongjian
- 通讯作者:He,Dongjian
Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
用D-氨基酸氧化酶抑制剂调节NMDA受体功能:了解PCP处理的小鼠模型中的功能活性。
- DOI:10.1007/s11064-016-1838-8
- 发表时间:2016-02
- 期刊:
- 影响因子:4.4
- 作者:Sershen H;Hashim A;Dunlop DS;Suckow RF;Cooper TB;Javitt DC
- 通讯作者:Javitt DC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL C. JAVITT其他文献
DANIEL C. JAVITT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL C. JAVITT', 18)}}的其他基金
Auditory event-related potentials as in vivo preclinical assays of circuit engagement for E/I-based therapeutic development
听觉事件相关电位作为基于 E/I 的治疗开发的电路参与的体内临床前测定
- 批准号:
10717704 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
Neural Mechanisms of Reading Dysfunction in Schizophrenia
精神分裂症阅读障碍的神经机制
- 批准号:
10640071 - 财政年份:2020
- 资助金额:
$ 191.78万 - 项目类别:
Neural Mechanisms of Reading Dysfunction in Schizophrenia
精神分裂症阅读障碍的神经机制
- 批准号:
10200005 - 财政年份:2020
- 资助金额:
$ 191.78万 - 项目类别:
Neural Mechanisms of Reading Dysfunction in Schizophrenia
精神分裂症阅读障碍的神经机制
- 批准号:
10399585 - 财政年份:2020
- 资助金额:
$ 191.78万 - 项目类别:
Temporal dynamics of neurophysiological patterns as treatment targets in Sz
作为 Sz 治疗目标的神经生理模式的时间动态
- 批准号:
9055968 - 财政年份:2016
- 资助金额:
$ 191.78万 - 项目类别:
tDCS Augmentation of Cognitive Remediation in Schizophrenia
tDCS 增强精神分裂症认知修复
- 批准号:
8584098 - 财政年份:2013
- 资助金额:
$ 191.78万 - 项目类别:
tDCS Augmentation of Cognitive Remediation in Schizophrenia
tDCS 增强精神分裂症认知修复
- 批准号:
8717732 - 财政年份:2013
- 资助金额:
$ 191.78万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 191.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 191.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 191.78万 - 项目类别:














{{item.name}}会员




